AVTX vs COP · P/E 0.0, rev $441.0K vs P/E 19, rev $58.94B
Avalo Therapeutics Inc (AVTX) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the AVTX and COP stock pages for the full models.
Not investment advice.